India plans to squeeze more from both patented drugs and generics
This article was originally published in Scrip
India is sending a clear message to drug-makers that it needs value-for-money from pharmaceuticals with two policy initiatives that aim directly to cut drug prices. One concerns a pricing system for patented medicines, while the other looks to expand the distribution of cut-price unbranded generic medicines around five-fold by the end of 2012, and 25-fold by the end of 2017.
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.